Junshi Biosciences' phase 3 study of toripalimab combined with bevacizumab for liver cancer shows promise.

From GlobeNewswire: 2024-06-11 22:06:29

Shanghai Junshi Biosciences announced that a phase III study of its drug toripalimab in combination with bevacizumab for treating liver cancer met primary endpoints for progression-free and overall survival. Liver cancer is a major global health concern, with China being heavily impacted. The HEPATORCH study showed promising results, potentially offering a new treatment option for advanced liver cancer patients. Toripalimab is an anti-PD-1 monoclonal antibody that has shown efficacy in various cancers. Junshi Biosciences is dedicated to developing innovative therapies to benefit patients worldwide.



Read more at GlobeNewswire: Junshi Biosciences Announces Phase 3 Study of Toripalimab